Supplementary Figures 15 - 17, Table 8 from Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma

PDF file - 452KB, Independent validation; Validation of 1q23.3 survival association in independent cohorts; Figure S15: Expression of genes on 1q23.3 in an independent cohort 3; S16: Expression of genes on 1q23.3 as in Supplemental Figure S15, but in the Spanish (a-b) and DFCI (c-d) cohorts. Panels (a) and (c) are for samples with 1q23.3 gain or amplification (log2 copy number ratio > 0.15), (b) and (d) for patients without amplification; S17: Panel (a): No association of overall survival after surgery and 1q23.3 amplification in an inde- pendent cohort from DFCI. (b) No significant association of 1q23.3 amplification and OS after recurrence, possibly due to small patient numbers; Table S8: Overall survival (OS) Hazard Ratios (HRs) of genes in the three peaks, available on the Affymetrix HGU133 Plus 2.0 genechip and displaying patterns of gene expression different from background noise as identified by the Sleipnir library 1. The LMX1A gene was flat, i.e., showed minimum expression intensity in all patients. Table S9: Overall survival (OS) Hazard Ratios (HRs) of genes in 1q21.2 as in Supplementary Table S8.